OpGen’s Subsidiary Curetis Meets Milestones in Collaborative Research Project with InfectoGnostics
April 03 2023 - 7:30AM
OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a
precision medicine company harnessing the power of molecular
diagnostics and bioinformatics to help combat infectious disease,
reported today that it has completed two interim milestones as part
of its collaboration project with InfectoGnostics under the PREPLEX
grant. The InfectoGnostics Research Campus Jena is a public-private
partnership breaking new ground in the diagnosis of infections.
More than 30 partners from science, medicine and industry are
jointly developing novel solutions for fast and cost-effective
diagnostics of infectious diseases.
Funded as part of the PREPLEX project, the two
specific interim milestones now completed contribute to the project
collaboration focused on artificial intelligence (AI) powered assay
development for phenotypic carbapenemase resistance in Gram
negative bacteria.
Following sample collection over the course of
one year, various testing methods to detect carbapenemase
resistance were evaluated during this phase of the collaboration.
Novel markers were identified for phenotypic carbapenemase
resistance in Klebsiella pneumoniae and Pseudomonas aeruginosa, two
of the pathogens of concern on the World Health Organization’s
(WHO) list. These markers were also confirmed and validated using
the proprietary ARESdb database at OpGen’s subsidiary Ares Genetics
in Vienna, Austria. The Ares team applied its unique machine
learning (ML) and AI capabilities to support the research
project.
Dr. Gerd Luedke, Director Innovation, Technology
and IP at OpGen’s subsidiary Curetis commented: “We are excited to
complete several key milestones in this joint research
collaboration. We believe that the discovery of novel biomarkers
for antimicrobial resistance will be crucial in developing novel
cutting-edge tools to fight the ever-growing threat of
antimicrobial resistance (AMR) and enhance antibiotic stewardship
in our hospitals. And seeing the AI that our colleagues at Ares
have developed successfully validate the research work is extremely
gratifying. This success could open up the potential for additional
collaborative work being conducted under the PREPLEX project which
could provide additional funding of a few hundred thousand dollars
to OpGen’s Curetis research team in the coming years.”
About OpGen,
Inc.
OpGen, Inc. (Rockville, Md., U.S.A.) is a
precision medicine company harnessing the power of molecular
diagnostics and bioinformatics to help combat infectious disease.
Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH,
we are developing and commercializing molecular microbiology
solutions helping to guide clinicians with more rapid and
actionable information about life threatening infections to improve
patient outcomes, and decrease the spread of infections caused by
multidrug-resistant microorganisms, or MDROs. OpGen’s current
product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the
ARES Technology Platform including ARESdb, NGS technology and
AI-powered bioinformatics solutions for antibiotic response
prediction including ARESiss, ARESid, ARESasp, and AREScloud, as
well as the Curetis CE-IVD-marked PCR-based SARS-CoV-2 test
kit.
For more information, please
visit www.opgen.com.
Forward-Looking Statements
This press release includes statements regarding
the Company’s PREPLEX research collaboration project with
InfectoGnostics. These statements and other statements regarding
OpGen’s future plans and goals constitute "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934 and
are intended to qualify for the safe harbor from liability
established by the Private Securities Litigation Reform Act of
1995. Such statements are subject to risks and uncertainties that
are often difficult to predict, are beyond our control, and which
may cause results to differ materially from expectations. Factors
that could cause our results to differ materially from those
described include, but are not limited to, the success of our
commercialization efforts, our ability to successfully, timely and
cost-effectively develop, seek and obtain regulatory clearance for
and commercialize our product and services offerings, the rate of
adoption of our products and services by hospitals and other
healthcare providers, the fact that we may not effectively use
proceeds from recent financings, the continued impact of COVID-19
on the Company’s operations, financial results, and
commercialization efforts as well as on capital markets and general
economic conditions, our ability to satisfy debt obligations under
our loan with the European Investment Bank, the effect of the
military action in Russia and Ukraine on our distributors,
collaborators and service providers, our liquidity and working
capital requirements, the effect on our business of existing and
new regulatory requirements, our ability to realize any anticipated
benefits from the reverse stock split, including maintaining its
listing on the Nasdaq Capital Market and attracting new investors,
and other economic and competitive factors. For a discussion of the
most significant risks and uncertainties associated with OpGen's
business, please review our filings with the Securities and
Exchange Commission. You are cautioned not to place undue reliance
on these forward-looking statements, which are based on our
expectations as of the date of this press release and speak only as
of the date of this press release. We undertake no obligation to
publicly update or revise any forward-looking statement, whether as
a result of new information, future events or otherwise.
OpGen:Oliver SchachtPresident and
CEOInvestorRelations@opgen.com
OpGen Investor & Press Contact:Alyssa
FactorEdison Groupafactor@edisongroup.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jul 2023 to Jul 2024